Straits Times Index
3,296.68 +23.96 (+0.73%) Nikkei
38,324.43 +772.27 (+2.06%) Hang Seng
17,083.41 +254.48 (+1.51%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,632.21 +33.16 (+0.05%) CMC Crypto 200
1,434.64 +19.88 (+1.41%)
Aeterna Zentaris Inc. (AEZS.TO)
| Previous close | 2.6600 |
| Open | 2.6800 |
| Bid | 2.6200 x 0 |
| Ask | 2.7700 x 0 |
| Day's range | 2.6600 - 2.6800 |
| 52-week range | 1.9100 - 4.4500 |
| Volume | |
| Avg. volume | 1,898 |
| Market cap | 12.917M |
| Beta (5Y monthly) | 2.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.6900 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Aug 1999 |
| 1y target est | N/A |
GlobeNewswireCeapro Receives Final Court Approval for Merger with Aeterna Zentaris
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate comple
ZacksAeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireAeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger of equals transaction with Ceapro, Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, March 27, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercia
